COMMUNIQUÉS West-GlobeNewswire

Communiqué établissant le bilan semestriel du contrat de liquidité de la société CROSSJECT
04/02/2026
Communiqué de Presse Communiqué établissant le bilan semestriel du contrat de liquidité de la société CROSSJECT Dijon, le 04 février 2026 Au titre du contrat de liquidité confié par la société CROSSJECT à Rothschild [...]
CROSSJECT - NOVEMBRE 2026 : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) la société pharmaceutique de [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ la société pharmaceutique de [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) la société pharmaceutique de [...]
SAFE - Croissance de 6,5 % du chiffre d’affaires 2025 - Confirmation de la feuille de route
04/02/2026
Croissance de 6,5 % du chiffre d’affaires 2025 Confirmation de la feuille de route Fleurieux-sur-l’Arbresle - France - le 4 février 2026 à 18h. Safe Group publie son chiffre d’affaires annuel consolidé pour l'exercice [...]
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the [...]
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
04/02/2026
T he Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, [...]
TruFull CBD Gummies | Launch "CBD Gummies Safe Relieves Anxiety Effective Reduces Pain & Stress With TruFull CBD 2026
04/02/2026
Discover TruFull CBD Gummies 2026 – A trusted, hemp-based CBD supplement created to help manage stress, and support physical comfort safely. New York City, Feb. 04, 2026 (GLOBE NEWSWIRE) -- In today’s fast-paced [...]
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
04/02/2026
Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra [...]
‘Think Mortgage Calculator, But for Lung Cancer Risk’: A More User-Friendly Self-Serve Tool Gives Canadians and Healthcare Providers a Clearer Starting Point
04/02/2026
A simple online tool offered by Lung Health Foundation helps people understand their potential lung cancer risk – no medical knowledge, paperwork or special access required TORONTO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- [...]
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
04/02/2026
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersen The high-dose regimen of [...]
Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™
04/02/2026
Two-year follow-up data demonstrate sustained benefit, including improvements in pain, fatigue and bone health, following single low dose of avigbagene parvec (FLT201) Robust improvements in lyso-Gb1, a surrogate [...]
New Study Finds Use of Psychiatric Collaborative Care Model Has Expanded Rapidly for Children and Adults, but With Enormous Disparities Among States
04/02/2026
Key organizations call on 14 state Medicaid agencies to reimburse for CoCM to improve patient outcomes and reduce total healthcare costs for Medicaid, Medicare and commercial plans WASHINGTON, Feb. 04, 2026 (GLOBE [...]
Cannara annonce un placement privé stratégique sans intermédiaire de 6,3 millions $ CA au prix de 2,10 $ CA par action ordinaire
04/02/2026
MONTRÉAL, 04 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de [...]
Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share
04/02/2026
MONTREAL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies
04/02/2026
SAN DIEGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development , describing the application of [...]
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026
04/02/2026
GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and [...]
Hyperion DeFi Announces Institutional Volatility Income Vault Built on Rysk Protocol
04/02/2026
Productizes On-chain Strategy Designed to Enhance Yield and Ecosystem Rewards through Gated Institutional Access LAGUNA HILLS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi [...]

Pages